Abbott has received US Food and Drug Administration approval to market Humira (adalimumab) as a treatment to reduce signs and symptoms of polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.
In the US, juvenile idiopathic arthritis is commonly referred to as juvenile rheumatoid arthritis (JRA). Humira is the first biologic treatment to receive UD FDA approval for this condition since 1999, and the first to be administered by injection in these patients once every two weeks.
JIA is the most common chronic rheumatic disease in children with onset before age 16. Typical symptoms include stiffness when awakening, limping, and joint swelling. Any joint can be affected and inflammation may limit the mobility of the affected joints. While it was once believed that most children eventually outgrow JIA, it is now known that between 25 and 70 percent of children with JIA will still have active disease into adulthood.